A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)

Trial Profile

A Phase II Trial of the Effect of Perindopril on HFSR Incidence and Severity in Patients Receiving Regorafenib With Refractory Metastatic Colorectal Carcinoma (mCRC)

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 17 Jul 2017

At a glance

  • Drugs Regorafenib (Primary) ; Perindopril
  • Indications Colorectal cancer; Erythrodysaesthesia
  • Focus Adverse reactions
  • Acronyms PARICCA
  • Most Recent Events

    • 11 Jul 2017 Planned End Date changed from 1 Jan 2019 to 1 Jan 2018.
    • 11 Jul 2017 Status changed from recruiting to active, no longer recruiting.
    • 15 Dec 2016 Planned primary completion date changed from 1 Dec 2017 to 1 Jan 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top